Pricing
NeogeniQS is an enterprise platform for clinical-trial operations and the eTMF, priced by study and scope, never by seat. Choose the suites and agents you need, size them to your study, and see the number before you ever talk to us.
Sound familiar?
You've been burned before. A platform that looked simple on the page turned into per-seat surprises, a two-year lock-in, and a security review that stalled the whole thing for a quarter.
And the part no one says out loud:
It doesn't have to be this way
We publish the model and the prices. What you pay follows the agents, studies, and integrations you actually use. Your data stays yours and portable, and nothing about the contract locks up your ability to leave.
Plans
Every plan is the full agentic platform. What changes between them is the size of the study it runs on. Prices are annual, per study, for the full four-suite platform.
Emerging biotech · research sites
The full platform on a first-in-human or single Phase I study. Design-partner pricing available for a reference story.
Start a pilotPhase II sponsors · CROs
The full agentic workforce on a Growth-band study, covering build, data, biostatistics, and an inspection-ready eTMF.
Get a scoped quotePharma sponsors · large CROs
Phase III/IV and multi-study programs, with CSV, data residency, priority support, and volume pricing across your portfolio.
Talk to an expertPrefer to buy just one suite or a single agent? You can. See the full rate card below.
How pricing works
Pay for the platform base, add the suites you use, then add the usage you need on top. One thing scales all of it, and that's the size of your study.
Per study · year
Every plan starts here. You get an inspection-ready eTMF, project-management dashboards, and the AI-triaged Study Support Desk. The suites and usage bolt onto this foundation.
Priced on each suite's natural unit
Bring on Study Build (per protocol), Data & Oversight (per participant), and Biostatistics & Reporting (per deliverable) when your program needs them.
Per language · connector · region
Switch on translation, EDC/RTSM integrations, CSV/GxP validation, data residency, and your support tier as you go. You only pay for what you turn on.
The full rate card
Pick your study-size band and see exactly what each suite and agent costs. Nothing hidden. This is the same model your proposal is built from.
Growth · 51–300 participants · 6–25 sites · Phase II
Prices are annual, per study, and scale directly with the band (S ×0.5 · M ×1 · L ×2 · XL ×3). Buying a suite, or the full platform, is always cheaper than summing individual agents. Figures are anchoring list prices; your proposal is scoped to the agents, integrations, and validation you actually use.
Usage & add-ons
Layer-3 dimensions sit on top of the platform and suites. Each is optional and priced on its own natural unit.
| Add-on | Unit | Price |
|---|---|---|
| ICF translation | Per language / study | $600–1,200 |
| Consented site / physician messaging | Per study / yr | ~$2,000 + volume |
| Integrations & connectors (Medidata, Oracle, Veeva, RTSM) | Per connector | $8–15k setup + $6–12k / yr |
| Computer System Validation (CSV / GxP) package | Per deployment (×0.5 / ×1 / ×2 / ×3) | $20k · $40k · $80k · $120k |
| Data residency (EU / other region) | % of subscription | +15–20% |
| Onboarding & implementation | % of Year-1 ACV | 20–30% |
| Support tier | Standard · Priority · Dedicated | Included · +15% · +25% |
Ways to save
Commit further and pay less. As a pre-launch platform, we work closely with early-access partners on scoped pilots.
Save 20% when you pay annually, up front.
10 / 20 / 30% off at 3 / 6 / 12 committed studies.
40–60% off, or a free pilot in exchange for a reference case study.
For recruitment- and timeline-linked agents, an optional success fee per milestone.
What you're actually paying for
This isn't another point tool to bolt onto the stack. It's one agentic platform that runs the whole trial and keeps it inspection-ready, so the handoffs between an EDC, a CTMS, a coding tool, a statistical environment, and a separate eTMF stop being your problem.
| Capability | NeogeniQS | eTMF / EDC incumbents | Point AI tools | DCT platforms |
|---|---|---|---|---|
| End to end, protocol → submission in one platform | ||||
| Agentic AI that does the work, not just recommends it | ||||
| Statistical + CSR submission back-end (SDTM/ADaM/TLF, CSR) | ||||
| Continuous, one-click inspection-readiness | ||||
| Humans in control of grounded, traceable, reviewed output | ||||
| Right-sized for emerging biotech & sites |
Built for your organization
Whether you run one study or a global portfolio, the same model scopes to your reality rather than forcing you into a fixed plan.
Run agentic AI across a portfolio with the governance, validation, and audit trails an inspection-ready program demands. Enterprise band, multi-study MSA.
Put more studies through the same team while output stays consistent and standards-fluent across every sponsor. Volume pricing applies across your book of studies.
Give your site network AI-assisted consent, source review, and eTMF on the Starter band, without the enterprise overhead you don't need.
Begin lean on a single study with design-partner pricing, then expand across the lifecycle as your pipeline grows.
No lock-in
A pricing decision shouldn't feel like a trap. Ownership and portability are part of the agreement, so your leverage doesn't disappear the day you sign.
Your source data, documents, datasets, and the eTMF remain yours throughout the engagement. We are the processor; you are the controller.
If you leave, your records, including the eTMF and its 21 CFR Part 11 audit trail, are exported in full and in usable formats. Nothing is held hostage.
Deliverables follow CDISC (SDTM, ADaM, Define.xml) and the TMF Reference Model, so your outputs stay portable and inspection-ready outside the platform.
Contract length, renewal, and offboarding are discussed openly during scoping, no multi-year handcuffs disguised as a discount.
How to start
No public sign-up wall and no obligation. Here is exactly what happens from first conversation to a scoped quote.
Tell us about the studies you run and the work that's slowing you down. We listen before we say anything, because the point is to understand your program rather than steer you into a tier.
We walk through the agents that fit your pain, working on your kind of study, with honest answers including on the limits.
We work your security review and procurement process directly, handling questionnaires, architecture, validation, and data-residency details under NDA.
You receive a proposal built to your suites, studies, integrations, and compliance needs, with the drivers of the number laid out plainly.
Built for regulated trials
Every agent runs inside a validated, audit-ready platform aligned to the standards clinical teams and inspectors expect.
Electronic records and signatures with full audit trails, access controls, and validation.
Good Clinical Practice, including risk-based quality management and computerized-system expectations.
Standards-based data capture, tabulation, and analysis datasets that validate clean in Pinnacle 21.
PHI safeguards, de-identification, and role-based access across the platform, with a signed BAA for every healthcare entity we work with.
Breach-notification and enforced-security obligations that extend HIPAA to us as your business associate.
Lawful processing, data-subject rights, and EU data-residency support for global trials.
Security, availability, and confidentiality controls audited against Trust Services Criteria.
Certified information-security management system governing the whole platform.
AI management system for responsible, governed, and auditable use of AI.
Whenever you're ready, we'll put together a proposal tailored to your studies, integrations, and compliance needs. Honest answers, no pressure.
